Deals
Pfizer Is Weighing Sale of $2 Billion-Women's Health Portfolio
- U.S. drugmaker is gauging interest from potential buyers
- Suitors likely to include private equity firms and drugmakers
This article is for subscribers only.
Pfizer Inc. is reviewing options including a sale of its women’s health portfolio as the U.S. pharmaceutical giant seeks to focus on developing treatments with higher growth potential, according to people with knowledge of the matter.
The drugmaker is working with financial advisers to gauge the interest of potential buyers, the people said, asking not to be identified because the deliberations are private. A sale of the division, which has annual sales of roughly $1.2 billion, could fetch about $2 billion and draw bids from both private equity firms and rival pharmaceutical companies, they said.